

**OPTN Liver and Intestinal Organ Transplantation Committee
National Liver Review Board (NLRB) Subcommittee
Meeting Summary
July 8, 2021
Conference Call**

James Trotter, MD, Chair

Introduction

The National Liver Review Board (NLRB) Subcommittee (the Subcommittee) met via Citrix GoToMeeting teleconference on 07/08/2021 to discuss the following agenda items:

1. Hepatocellular Carcinoma (HCC) Candidates Treated and Recur
2. HCC Candidates Beyond Downstaging
3. Next Round of NLRB Diagnoses

The following is a summary of the Subcommittee's discussions.

1. Hepatocellular Carcinoma (HCC) Candidates Treated and Recur

The Subcommittee discussed updating policy/guidance to remove the six- month waiting period for HCC candidates who are treated and recur.

Summary of discussion:

A member reported that scenarios in which candidates are treated for HCC and then recur are infrequent at his or her center. Other members agreed, but remained interested in modifying guidance so that candidates in this situation would receive Median MELD at Transplant (MMaT) -3 without having to observe a six- month waiting period.

UNOS staff shared data on waiting time for HCC exception candidates listed from 2/4/2020-3/31/2021. Subcommittee members requested data from the year prior for comparison.

Next steps:

The Subcommittee will discuss which timeframe is most appropriate for HCC candidates who are treated and recur.

2. HCC Candidates Beyond Downstaging

The Subcommittee discussed prior review of candidates beyond downstaging to determine if any update is necessary.

Summary of discussion:

A member explained that they would like to consider allowing more advanced HCC to be downstaged. Other members responded that they would be interested in any data or literature on the topic. Another member added that they would assist in gathering data on candidates with T3 HCC.

Next steps:

The Committee will temporarily table the issue and circle back once members have completed a literature search.

3. Next Round of NLRB Diagnoses

The Subcommittee began discussions on the next round of diagnoses for review.

Summary of discussion:

The Subcommittee confirmed that their next round of diagnoses for review should include:

Policy-

- Cholangiocarcinoma (CCA)
- Hepatic Artery Thrombosis (HAT)
- Primary Hyperoxaluria

Guidance-

- Ischemic Cholangiopathy
- Polycystic Liver Disease (PLD)
- Post-Transplant Complications:
 - Small for Size Syndrome
 - Late Vascular Complications

Subcommittee members indicated interest in reviewing particular diagnoses. A member suggested reviewing Atypical Hemolytic Uremic Syndrome (HUS) in future.

Next steps:

Subcommittee members will form groups, review these diagnoses, and present any recommendations for changes during upcoming meetings.

Upcoming Meeting

- August 12, 2021

Attendance

- **Subcommittee Members**
 - James Eason
 - Alan Gunderson
 - Jennifer Kerney
 - Greg McKenna
 - Jorge Reyes
 - James Trotter
 - Kymberly Watt
- **HRSA Representatives**
 - Jim Bowman
 - Marilyn Levi
- **SRTR Staff**
 - Katie Audette
 - Andrew Wey
- **UNOS Staff**
 - Nicole Benjamin
 - Hannah Brown
 - Julia Foutz
 - Betsy Gans
 - Jennifer Musick
 - Megan Oley
 - Kelley Poff
 - Leah Slife
 - Niyati Upadhyay
 - Samantha Weiss